UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge

Nature communications, 2023-09, Vol.14 (1), p.5925-5925, Article 5925

2023

Volltextzugriff (PDF)

Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus

Viruses, 2022-10, Vol.14 (11), p.2327

2022

Volltextzugriff (PDF)

VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes

Journal of medical virology, 2023-01, Vol.95 (1), p.e28108-n/a

2023

Volltextzugriff (PDF)

Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes

Biomedicines, 2020-11, Vol.8 (11), p.484

2020

Volltextzugriff (PDF)

Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1

Molecular therapy. Oncolytics, 2023-03, Vol.28, p.334-348

2023

Volltextzugriff (PDF)

CpG Oligodeoxynucleotides as TLR9 Agonists: Therapeutic Applications in Cancer

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2009, Vol.23 (6), p.361-375

2009

Volltextzugriff (PDF)

Prophylactic Vaccination and Intratumoral Boost with HER2-Expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response against HER2-Positive Tumor Cells

Vaccines (Basel), 2023-12, Vol.11 (12), p.1805

2023

Volltextzugriff (PDF)

False Negative Results in Clostridium difficile Testing

BMC infectious diseases, 2016-08, Vol.16 (1), p.430, Article 430

2016

Volltextzugriff (PDF)

Impact of polymerase chain reaction testing on Clostridium difficile infection rates in an acute health care facility

American journal of infection control, 2015-04, Vol.43 (4), p.383-386

2015

Volltextzugriff (PDF)

Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells

European journal of cancer (1990), 2014-03, Vol.50 (4), p.713-721

2014

Volltextzugriff (PDF)

Molecular targeting of CEACAM6 using antibody probes of different sizes

Journal of controlled release, 2012-07, Vol.161 (1), p.18-24

2012

Volltextzugriff (PDF)

CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy

Expert opinion on biological therapy, 2007-08, Vol.7 (8), p.1257-1266

2007

Volltextzugriff (PDF)

Complete Genome Sequence of Enterococcus thailandicus Strain a523 Isolated from Urban Raw Sewage

Genome announcements (Washington, DC), 2017-11, Vol.5 (47)

2017

Volltextzugriff (PDF)

Analysis of two Clostridium difficile outbreaks in an acute health care facility

Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie médicale et l'infectiologie Canada, 2017-09, Vol.1 (2), p.23-31

2017

Volltextzugriff (PDF)

Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)

Heliyon, 2016-08, Vol.2 (8), p.e00147-e00147, Article e00147

2016

Volltextzugriff (PDF)

Newly Developed Oncolytic Herpes Simplex Viruses Expressing Multiple Immunomodulatory Transgenes Effectively Target AML Cells

Blood, 2021-11, Vol.138 (Supplement 1), p.1169-1169

2021

Volltextzugriff (PDF)

CpG Oligodeoxyneucleotides as TLR9 Agonists: Therapeutic Applications in Cancer

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2009-12, Vol.23 (6), p.361-375

2009

Volltextzugriff (PDF)

The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2580-2580

2023

Volltextzugriff (PDF)

Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4105-4105

2024

Volltextzugriff (PDF)

T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis

Cellular Immunology, 2005-06, Vol.235 (2), p.98-108

2005

Volltextzugriff (PDF)

Initial results from a first in human trial incorporating accelerated dose titration of a novel immune stimulating oncolytic virus - VG161

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e14574-e14574

2021

Volltextzugriff (PDF)

Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases

Oncology letters, 2024-06, Vol.27 (6), Article 244

2024

Volltextzugriff (PDF)

Abstract 5641: Synergy of immunomodulators delivered by an HSV-1 oncolytic virus can enhance its therapeutic effects in vivo

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5641-5641

2018

Volltextzugriff (PDF)

Abstract B85: Anticancer efficacy of a novel immune-stimulating oncolytic virus: VG161 in gastrointestinal cancers

Cancer immunology research, 2020-04, Vol.8 (4_Supplement), p.B85-B85

2020

Volltextzugriff (PDF)

Abstract B059: Synergistic activation of antitumor immunity by an oncolytic virus VG161 armed with multiple immune-stimulating genes

Cancer immunology research, 2019-02, Vol.7 (2_Supplement), p.B059-B059

2019

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)
Dissertationen
(1)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge

Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus

VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes

Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes

Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1

CpG Oligodeoxynucleotides as TLR9 Agonists: Therapeutic Applications in Cancer

Prophylactic Vaccination and Intratumoral Boost with HER2-Expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response against HER2-Positive Tumor Cells

False Negative Results in Clostridium difficile Testing

Impact of polymerase chain reaction testing on Clostridium difficile infection rates in an acute health care facility

Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells

Molecular targeting of CEACAM6 using antibody probes of different sizes

CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy

Complete Genome Sequence of Enterococcus thailandicus Strain a523 Isolated from Urban Raw Sewage

Analysis of two Clostridium difficile outbreaks in an acute health care facility

Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)

Newly Developed Oncolytic Herpes Simplex Viruses Expressing Multiple Immunomodulatory Transgenes Effectively Target AML Cells

CpG Oligodeoxyneucleotides as TLR9 Agonists: Therapeutic Applications in Cancer

The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors

Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI)

T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis

Initial results from a first in human trial incorporating accelerated dose titration of a novel immune stimulating oncolytic virus - VG161

Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases

Abstract 5641: Synergy of immunomodulators delivered by an HSV-1 oncolytic virus can enhance its therapeutic effects in vivo

Abstract B85: Anticancer efficacy of a novel immune-stimulating oncolytic virus: VG161 in gastrointestinal cancers

Abstract B059: Synergistic activation of antitumor immunity by an oncolytic virus VG161 armed with multiple immune-stimulating genes

Suchergebnisse filtern